Spots Global Cancer Trial Database for Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer

Official Title: Study to Analyze the Predictive Role of Factors Implicated in the Signaling Pathway of the EGFR in Response to Treatment With Neoadjuvant Chemoradiotherapy in Patients With Cancer of the Esophagus or Rectum

Study ID: NCT00628368

Conditions

Colorectal Cancer

Esophageal Cancer

Interventions

gene expression analysis

mutation analysis

polymorphism analysis

laboratory biomarker analysis

biopsy

endoscopic biopsy

Study Description

Brief Summary: RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This clinical trial is studying how well biological factors work in predicting response to treatment in patients with esophageal cancer or rectal cancer.

Detailed Description: OBJECTIVES: Primary * Analyze various biological factors that can be used as markers to predict response to treatment and correlate with the signaling pathway of EGFR. Secondary * Establish a tissue bank to store information about the response to treatment and survival. OUTLINE: Patients undergo endoscopy, 11 biopsies of tumor tissue, and 3 biopsies of healthy mucosa. Blood samples are also collected. Samples are analyzed for the expression of 4 receptors in the EGFR family, polymorphisms at intron 1 of the EGFR gene, and gene mutations in downstream signaling pathways. After surgery, patients are followed every 3 months.